Key Highlights
- 20/20 Biolabs shares fell 45.96% over one month to $0.254 as screened on Friday, October 23, 2026.
- The past week brought a 9.29% decline, with the latest session up 1.32%.
- Record multi-cancer test revenue was reported for the second quarter on August 17.
- Trailing twelve-month revenue is about $2.04 million against a net loss near $7.12 million.
- Market value is about $3.45 million on roughly 12.77 million shares.
20/20 Biolabs Stock: Why Did Shares Fall 45.96% in a Month?
20/20 Biolabs (NASDAQ:AIDX) traded at $0.254 on Friday, October 23, 2026, down 45.96% over one month and 9.29% over one week, with the latest session up 1.32%. No financing, reverse split or compliance notice appears in the company's releases for the period. The decline came alongside a run of investor-relations events rather than a disclosed negative event.
Health Services, the group the screen places it in, rose 9.54% in the same month, so the stock lagged by about 55.5 percentage points (calculated). At under $1, it is a penny stock.
OneTest Revenue: What Did the August Report Show?
20/20 Biolabs develops AI-powered, lab-based blood tests for early detection of cancer and chronic disease. Its main product is OneTest for Cancer, a multi-cancer early detection test, and it also offers OneTest for Longevity and runs a CLIA laboratory for overseas diagnostics startups.
On August 17 the company reported second-quarter 2026 results with record quarterly revenue from its flagship cancer test. Full-year 2025 revenue was $2.05 million, up 16.71%, with a net loss of $3.74 million, which was 32.65% smaller than in 2024.
Cash and Share Base: Why Does the Balance Sheet Matter Here?
Trailing twelve-month revenue is about $2.04 million, up 2.7%, with a trailing net loss near $7.12 million. The first-quarter 2026 release cited a cash position of $4.2 million as of March, so cash relative to the loss rate is the central question for the stock.
With roughly 12.77 million shares and a price near $0.27 on October 21, market value was about $3.45 million, below the $4.2 million March cash figure (calculated comparison). The market is therefore attaching little value to the business beyond its cash and is pricing in the chance of dilution.
Nasdaq requires a $1.00 minimum bid, and the current price is well below it, so a bid-price notice would be a further compliance item to watch.
Webinars and Conferences: What Was Said About the FDA Advisory Committee Vote?
On September 29 the company announced an investor webinar for October 7 covering an FDA Advisory Committee vote and a new OneTest franchise model. It also announced participation in the Maxim Growth Summit in New York on October 14, with one-on-one investor meetings.
The stock fell through this period, showing that the events did not lift sentiment. Details of the committee vote and the franchise terms are not quantified in the announcements.
What to Watch Next: Can OneTest Revenue and Cash Steady AIDX?
The next quarterly report will show whether record cancer-test revenue continues and how much cash remains. Any financing, reverse split or Nasdaq bid notice would be material for a stock at $0.254. Results are the next scheduled event for the company.






Please wait processing your request...